Versant Capital Management’s Utah Medical Products UTMD Stock Holding History

Versant Capital Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.4K	Sell	440 -6	-1%	-$399	﹤0.01%	1711
2026 Q1	$27.6K	Buy	446 +6	+1%	+$378	﹤0.01%	1635
2025 Q4	$24.6K	Sell	440 -77	-15%	-$4.46K	﹤0.01%	1508
2025 Q3	$32.6K	Buy	517 +77	+18%	+$4.55K	﹤0.01%	1286
2025 Q2	$25K	Buy	+440	New	+$23.9K	﹤0.01%	1390
2025 Q1	–	Sell	-198	Closed	-$12.2K	–	2628
2024 Q4	$12.2K	Buy	+198	New	+$12.8K	﹤0.01%	1300

Other funds holding UTMD

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

HFS

Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

Versant Capital Management's UTMD Position: Q2 2026 in Review

Versant Capital Management reduced its Utah Medical Products (UTMD) stake by 1.3% in Q2 2026, selling an estimated $399 and leaving 440 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Versant Capital Management first reported a position in UTMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $32.6K in Q3 2025. 8 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

Versant Capital Management held 440 shares of Utah Medical Products worth $30.4K as of Q2 2026.
Versant Capital Management sold 6 Utah Medical Products shares in Q2 2026, an estimated $399.
Utah Medical Products made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1711 holding.
Versant Capital Management first reported a position in Utah Medical Products in Q4 2024 and has held it in 6 quarters since.
Versant Capital Management's Utah Medical Products position peaked at $32.6K in Q3 2025.
8 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.